Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

statement as a result of new information, future events or other factors. Forward- looking statements are inherently uncertain, and investors must recognize that events could differ significantly from our expectations. In addition to the risks and uncertainties noted in this release, there are certain factors that could cause actual results to differ materially from those anticipated by some of the statements made. These include: (1) the ability to achieve business plans, including with respect to lower income consumers and growing existing sales and volume profitably despite high levels of competitive activity, especially with respect to the product categories and geographical markets (including developing markets) in which the Company has chosen to focus; (2) the ability to successfully execute, manage and integrate key acquisitions and mergers, including (i) the Domination and Profit Transfer Agreement with Wella, and (ii) the Company's merger with The Gillette Company, and to achieve the cost and growth synergies in accordance with the stated goals of these transactions; (3) the ability to manage and maintain key customer relationships; (4) the ability to maintain key manufacturing and supply sources (including sole supplier and plant manufacturing sources); (5) the ability to successfully manage regulatory, tax and legal matters (including product liability, patent, and intellectual property matters as well as those related to the integration of Gillette and its subsidiaries), and to resolve pending matters within current estimates; (6) the ability to successfully implement, achieve and sustain cost improvement plans in manufacturing and overhead areas, including the Company's outsourcing projects; (7) the ability to successfully manage currency (including currency issues in volatile countries), debt, interest rate and commodity cost exposures; (8) the ability to manage continued global political and/or economic uncertainty and disruptions, especially in the Co
'/>"/>
SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... N.J. , Sept. 19, 2014 Merck (NYSE: ... States and Canada , is teaming ... Desafiando La Diabetes: Logra Tus Metas , an educational program encouraging ... blood sugar -- a key treatment goal to help reduce the ... States are at a higher risk for developing type ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. Merlo ... CVS ), will speak before the National Press Club in ... the company,s recent move to stop selling tobacco products and ... future of health. "Dramatic changes in our health ... providers and government," Merlo has said. "CVS Health has a ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... , AT A GLANCE , Positron emission mammography ... ability to differentiate between benign and cancerous lesions. ... of suspicious lesions found. , An NIH-sponsored, ... cancer found that Positron Emission Mammography (PEM) scanners significantly ...
... , WOODCLIFF LAKE, N.J., Oct. 29 Eisai Inc. and ... the recipient of the 2009 C.A.R.E. Pharmacy Award. ... Greene is being recognized for the critical role she has ... Alzheimer,s disease. As a Geriatric Consultant Pharmacist with the ...
Cached Medicine Technology:High-Resolution Breast PET Improves Breast Cancer Detection 2High-Resolution Breast PET Improves Breast Cancer Detection 3Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 2Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 3
(Date:9/19/2014)... 19, 2014) - New research published today in the ... cases could reach 6,800 in West Africa by the ... not enacted. , Arizona State University and Harvard ... rate of rise in cases significantly increased in August ... mass quarantine was put in place, indicating that the ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... Famous Vancouver company, Pro Ace Heating ... now become a one-stop-solution for heating, air conditioning, plumbing ... The company has achieved this status by providing a ... While there are many companies that provide these services ... vendor who can offer all of these services together ...
(Date:9/19/2014)... 2014 (HealthDay News) -- When it comes to firearm ... United States, while the District of Columbia has the ... decade, deaths from gun-related violence -- including murders, suicides ... States, the study revealed. Hawaii,s rate was roughly three ... spectrum, the District of Columbia had the highest rate ...
(Date:9/19/2014)... September 19, 2014 Recently, Top10BestSEOHosting.com ... announced that JustHost, IX Web Hosting and Bluehost ... , “As is known to most people, VPS ... a physical server computer into many servers, each ... running on someone’s own dedicated computer,” the manager ...
Breaking Medicine News(10 mins):Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2
... show injury in as little as 6 days , , ... drug Tysabri can start causing liver damage within six days ... In January, the U.S. Food and Drug Administration expanded the ... of the digestive tract. , The drug has also been ...
... in a severe form of the disorder, , , WEDNESDAY, Feb. 27 ... and a more severe form of the disease caused by one ... are the two main findings from a Massachusetts study that found ... 35 babies a year before 2003 to less than 20 babies ...
... net premiums written increase 22% over the ... comparable year-earlier quarterly results, FARMINGTON, Conn., Feb. 27 ... today announced its financial results for the fourth quarter ended,December ... http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ), -- Gross premiums written for ...
... (Nasdaq: ACUR ) announced that President and Chief,Executive ... for health,reasons for an as-yet undetermined period. Mr. Reddick ... Board of Directors. At the same time,the Company announced ... Chairman of the Board. Mr. Markham has been a ...
... Targeted Synergies Sells Rights to Bystolic(TM) (Nebivolol) for $370 ... To Consider a Sale of Dey ... MYL ),today announced its financial results for the three and nine ... for the Merck,Generics acquisition, and announced a number of strategic and ...
... 2008 Nektar,Therapeutics (Nasdaq: NKTR ) announced today ... ended December 31, 2007., Revenue totaled $65.8 million ... in the fourth quarter of 2006. For the year ... million compared to,$217.7 million in 2006., Cash, cash ...
Cached Medicine News:Health News:Tysabri May Cause Liver Damage, Health Officials Say 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 3Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter 2Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter 3Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter 4Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter 5Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter 6Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter 7Health News:Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board 2Health News:Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board 3Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 2Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 3Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 4Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 5Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 6Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 7Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 8Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 9Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 10Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 11Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 12Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 13Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 14Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 15Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 2Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 3Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 4Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 5Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 6Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 7Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 8Health News:Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results 9
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: